Latest Erectile Dysfunction News

Page 3 of 5
BPH Global Ltd is pioneering a novel seaweed-based natural formulation targeting male vitality, staking a first-mover claim in this emerging segment of men’s health. The company’s R&D, led by Gaia Mariculture, aims to launch an OTC supplement with potential for clinical validation.
Ada Torres
Ada Torres
12 Nov 2025
EVE Health Group has taken significant strides in commercialising its women’s and men’s health products Dyspro™ and Libbo™, securing regulatory clearances, first patient prescriptions, and raising $1.1 million to support market expansion.
Ada Torres
Ada Torres
31 Oct 2025
LTR Pharma has made significant strides towards its US market debut with ROXUS, bolstered by expert appointments and peer-reviewed clinical data validating its rapid-onset ED treatments.
Ada Torres
Ada Torres
29 Oct 2025
EVE Health Group Limited has launched a $1.1 million capital raising via a placement to fund the commercial rollout of its two pharmaceutical products, Dyspro and Libbo. The offer includes shares and options, with some subject to shareholder approval.
Ada Torres
Ada Torres
15 Oct 2025
EVE Health Group has raised $1.1 million to accelerate the commercial rollout of its innovative pharmaceutical products Dyspro and Libbo, signaling strong investor confidence in its growth strategy.
Victor Sage
Victor Sage
9 Oct 2025
LTR Pharma has increased its ownership in LevOmega to approximately 43% through a strategic A$1 million investment, reinforcing its commitment to sustainable, pharmaceutical-grade omega-3 development.
Victor Sage
Victor Sage
6 Oct 2025
LTR Pharma has acquired a one-third equity stake in LevOmega Pty Ltd at no cost to shareholders, positioning itself in the growing pharmaceutical-grade omega-3 sector. This strategic move complements LTR’s existing intranasal pharmaceutical portfolio and aligns with its innovation-driven growth strategy.
Victor Sage
Victor Sage
22 Sept 2025
Orthocell’s nerve repair device Remplir is being adopted in Australia for nerve-sparing prostate cancer surgeries, aiming to reduce erectile dysfunction and urinary incontinence post-operation. This development could significantly expand Remplir’s market reach globally.
Ada Torres
Ada Torres
16 Sept 2025
LTR Pharma’s FY25 results reveal a transformative year highlighted by SPONTAN’s rapid absorption and strategic partnerships that pave the way for US market entry.
Ada Torres
Ada Torres
29 Aug 2025
LTR Pharma Limited (ASX, LTP) reported significant progress in FY25, advancing its novel intranasal treatments for erectile dysfunction and expanding its commercial footprint in Australia and the US. The company secured key partnerships and capital raises, positioning itself for regulatory milestones and global market entry.
Ada Torres
Ada Torres
29 Aug 2025
LTR Pharma’s SPONTAN nasal spray has achieved unanimous patient satisfaction in treating erectile dysfunction after prostate surgery, signaling a promising shift in therapy preferences.
Ada Torres
Ada Torres
25 Aug 2025
LTR Pharma has announced that its erectile dysfunction treatment SPONTAN now boasts an 18-month shelf life, surpassing commercial standards and paving the way for international market growth.
Victor Sage
Victor Sage
22 Aug 2025